Organization (Industry)
INNATE PHARMA
ClinicalTrials.gov lists INNATE PHARMA as lead sponsor of 21 trials. It has 30 active development programs and 1 approved asset.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers INNATE PHARMA: 21 lead-sponsored trials and 3 legal-entity registrations.
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Disease areas (39)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Head and Neck Neoplasms | 6 |
| Lymphoma | 5 |
| Lymphoma, Non-Hodgkin | 5 |
| Carcinoma, Squamous Cell | 4 |
| Esophageal Neoplasms | 3 |
Showing 5 of 39 disease areas.
Trials by start year as sponsor or collaborator (19)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 2 |
| 2024 | 1 |
| 2023 | 2 |
| 2022 | 2 |
| 2021 | 1 |
| 2020 | 3 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 3 |
Showing 10 of 19 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (30)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| IPH5201 + durvalumab + standard chemotherapy | Lung Neoplasms | Phase 2 | 1 |
| IPH5201 + durvalumab + standard chemotherapy | Carcinoma, Non-Small-Cell Lung | Phase 2 | 1 |
| IPH4102 | Lymphoma, Non-Hodgkin | Phase 2 | 3 |
| IPH4102 | Lymphoma | Phase 2 | 3 |
| IPH4102 | Lymphoma, T-Cell, Cutaneous | Phase 2 | 2 |
Showing 5 of 30 active programs.
Approved assets (1)
| Drug | Trials |
|---|---|
| CETUXIMAB | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 17% hit target (n=6) | 43% on time (n=7) |
Journals published in (20)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation | 3 |
| The New England journal of medicine | 3 |
| Blood | 2 |
| Clinical cancer research : an official journal of the American Association for Cancer Research | 2 |
| Emerging microbes & infections | 2 |
Showing 5 of 20 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 95 | 26 | 2025-10-21 |
SEC-reported annual financials (10)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 10,158,633 | -55,477,081 | 49,208,172 |
| 2024 | 21,770,785 | -53,527,286 | 56,242,007 |
| 2023 | 66,702,989 | -8,191,652 | 60,622,554 |
| 2022 | 60,644,795 | -61,095,893 | 54,324,168 |
| 2021 | 29,208,335 | -62,440,309 | 55,576,593 |
| 2020 | 79,567,615 | -72,965,965 | 56,685,924 |
| 2019 | 95,821,551 | -23,278,910 | 70,531,991 |
| 2018 | 110,429,741 | 3,583,747 | 81,753,881 |
| 2017 | 49,613,972 | -54,517,567 | 75,491,930 |
| 2016 | not reported | not reported | not reported |
Financing and grant events (10)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2024-02-06 | Other financing | not disclosed | Edgar offerings |
| 2023-04-26 | Other financing | not disclosed | Edgar offerings |
| 2023-04-26 | ATM offering | not disclosed | Sec extracted |
| 2023-04-26 | ATM offering | not disclosed | Sec extracted |
| 2023-04-14 | ATM offering | not disclosed | Sec extracted |
Showing 5 of 10 events.
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| INNATE SRL | Novi Ligure Alessandria, IT | FDA | Innate Srl |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | 50.0% |
Organization relationships (4)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Institut Paoli-Calmettes | Co sponsors trial with | 2 |
| The Lymphoma Academic Research Organisation | Co sponsors trial with | 1 |
| Centre Hospitalier Universitaire de Rennes | Co sponsors trial with | 1 |
| Jules Bordet Institute | Co sponsors trial with | 1 |
Latest dated events (137)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-10-21 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-09-25 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-07-22 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 137 events.
Biomarker capability evidence (96)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALK | Trial sponsor | Named in trial inclusion criteria |
| CCT3 | Trial collaborator | Named in trial inclusion criteria |
| CD4 | Trial sponsor | Named in trial inclusion criteria |
| CDK4 | Trial collaborator | Named in trial inclusion criteria |
| CRP | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 96 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, clia clinical laboratory certificates, and biomarkers this organization publishes on.